Voyxact (sibeprenlimab) — Coverage Criteria for Primary IgA Nephropathy
Customize your policy alerts
Sign up for all Neighborhood Health Plan of Rhode Island policy alerts
Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Covers criteria for authorization and continuation of Voyxact for adults with primary immunoglobulin A nephropathy (IgAN) at risk for progression, including required clinical and lab documentation and quantity limits.
No material clinical or coverage changes in this revision.
Coverage Criteria for Voyxact (sibeprenlimab)
inv-01: COVERAGE CRITERIA — Initial authorization (6 months)
Covered when ALL of the following are met:
Initiation criteria
- A: Medication prescribed by or in consultation with a nephrologist.
- B: Member is 18 years of age or older.
- C: Documentation that member has a kidney biopsy confirming a diagnosis of primary immunoglobulin A nephropathy (IgAN).
- Documentation with laboratory report and/or chart note(s) within the previous 3 months indicating the member has proteinuria greater than or equal to 1 g/day OR baseline urine protein-to-creatinine ratio (UPCR) greater than or equal to 0.8 g/g based on a 24-hour urine collection.proteinuria >=1 g/day or UPCR >=0.8 g/g
24-hour urine collection required for proteinuria/UPCR measurement.
- E: Documentation that member's eGFR is ≥30 mL/min/1.73 m2.eGFR >=30
- F: Member is receiving a stable dose of maximally tolerated renin-angiotensin system (RAS) inhibitor therapy (eg, ACE inhibitor or ARB) for at least 3 months prior to initiation, or has documented intolerance/contraindication to RAS inhibitors.3 months
Examples: ACEI or ARB.
- G: Member is receiving a stable dose of maximally tolerated SGLT2 inhibitor for at least 3 months prior to initiation, or has documented intolerance/contraindication to SGLT2 inhibitors.3 months
- H: Documented inadequate response from a 30-day trial, intolerance, or contraindication to an oral glucocorticoid (eg, prednisone).30 days
- I: Member is not using medication in combination with Filspari, Tarpeyo, Vanrafia, or Fabhalta.
Combination therapy with listed agents is not permitted.
- J: Member is not currently receiving dialysis and has not undergone kidney transplant.
inv-02: COVERAGE CRITERIA — Continuation authorization (6 months)
Covered when ALL of the following are met:
Continuation criteria
- A: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
- B: Documentation of benefit from therapy as evidenced by either decreased proteinuria from baseline on 24-hour urine OR decrease in UPCR from baseline on 24-hour urine.
Either decreased absolute proteinuria or decreased UPCR from baseline required.
- C: Documentation that member's eGFR remains ≥30 mL/min/1.73 m2.eGFR >=30
- D: Member is not using medication in combination with Filspari, Tarpeyo, Vanrafia, or Fabhalta.
All indications other than the FDA-approved indication for primary immunoglobulin A nephropathy (IgAN) are considered experimental/investigational and are not medically necessary.
Use of Voyxact in combination with Filspari, Tarpeyo, Vanrafia, or Fabhalta is not permitted; concomitant administration with these agents is excluded from coverage.
Use of Voyxact for any indication outside the FDA-approved population for primary IgAN is considered not medically necessary and will not be covered.
Clinical Thresholds and Coding-related Values
Provider Requirements, Documentation, and Denial Risk
Prior Authorization Required
Prior authorization is required for initiation of therapy. Submit a prior authorization request with complete clinical documentation before starting treatment. The prescribing clinician must be a nephrologist or provide documentation of consultation with a nephrologist.
- Prior authorization required before initiation
- Prescriber = nephrologist or documented nephrology consult
- Requested duration: initial authorization up to 6 months
Missing Clinical Criteria May Lead to Denial
If the required clinical criteria are not included with the request, the claim is at high risk for denial. Missing or incomplete documentation commonly leads to denial or delay.
- Missing kidney biopsy confirming primary IgAN (required)
- Missing recent laboratory documentation within 3 months showing proteinuria ≥1 g/day or UPCR ≥0.8 g/g (based on 24-hour urine)
- Missing documentation of eGFR ≥30 mL/min/1.73 m2
- No documentation of stable maximally tolerated RAS inhibitor therapy for ≥3 months or documented intolerance/contraindication
- No documentation of stable maximally tolerated SGLT2 inhibitor therapy for ≥3 months or documented intolerance/contraindication
- No documentation of trial/intolerance/contraindication to a 30-day oral glucocorticoid trial when applicable
Required Clinical Documentation for Prior Authorization
Provide complete supporting documentation with the authorization request to avoid delays: nephrology prescription or consult note, kidney biopsy report confirming primary IgAN, and recent labs (within 3 months) including 24-hour urine protein or UPCR and eGFR. Include medication history documenting stable maximally tolerated RAS inhibitor and SGLT2i therapy for ≥3 months or documented contraindications/intolerances, and evidence of trial/intolerance of oral glucocorticoid if applicable.
- Nephrology prescription or consult note
- Kidney biopsy report confirming primary IgAN (required)
- Recent labs (within 3 months): 24-hour urine protein or UPCR and serum creatinine/eGFR
- Documentation of proteinuria ≥1 g/day or UPCR ≥0.8 g/g (24-hour collection)
- Documentation that eGFR ≥30 mL/min/1.73 m2
- Medication history showing stable maximally tolerated RAS inhibitor (ACEI/ARB) for ≥3 months, or documented intolerance/contraindication
- Medication history showing stable maximally tolerated SGLT2 inhibitor for ≥3 months, or documented intolerance/contraindication
- Documentation of 30-day oral glucocorticoid trial with inadequate response, or intolerance/contraindication
- Statement that patient is not on disallowed combination therapy (Filspari, Tarpeyo, Vanrafia, Fabhalta) and is not on dialysis or post-kidney transplant
Background and Regulatory Context
Voyxact (sibeprenlimab) received accelerated FDA approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. The approval is based on reductions in proteinuria; it has not been established whether Voyxact slows long-term decline in kidney function, and continued approval may depend on confirmatory trial evidence demonstrating clinical benefit.
Definitions and Regulatory Notes
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.